vs
Side-by-side financial comparison of Recon Technology, Ltd (RCON) and ROCKWELL MEDICAL, INC. (RMTI). Click either name above to swap in a different company.
ROCKWELL MEDICAL, INC. is the larger business by last-quarter revenue ($18.3M vs $12.2M, roughly 1.5× Recon Technology, Ltd). ROCKWELL MEDICAL, INC. runs the higher net margin — -3.0% vs -6.8%, a 3.8% gap on every dollar of revenue. On growth, Recon Technology, Ltd posted the faster year-over-year revenue change (111.0% vs -25.6%).
Recon Instruments Inc. was a Canadian technology company that produced smartglasses and wearable displays marketed by the company as "heads-up displays" for sports. Recon's products delivered live activity metrics, GPS maps, and notifications directly to the user's eye. Recon's first heads-up display offering was released commercially in October 2010, roughly a year and a half before Google introduced Google Glass.
Rockwell Medical Inc. is a publicly traded pharmaceutical company based in Wixom, Michigan and founded in 1996 that focuses on development and commercialization of treatments against diseases such as end-stage renal disease (ESRD) and chronic kidney disease (CKD).
RCON vs RMTI — Head-to-Head
Income Statement — Q2 FY2026 vs Q4 FY2025
| Metric | ||
|---|---|---|
| Revenue | $12.2M | $18.3M |
| Net Profit | $-832.7K | $-554.0K |
| Gross Margin | 33.5% | 21.1% |
| Operating Margin | -14.6% | -2.2% |
| Net Margin | -6.8% | -3.0% |
| Revenue YoY | 111.0% | -25.6% |
| Net Profit YoY | 70.5% | 26.7% |
| EPS (diluted) | $-0.09 | $-0.01 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $12.2M | $18.3M | ||
| Q3 25 | — | $15.9M | ||
| Q2 25 | — | $16.1M | ||
| Q1 25 | — | $18.9M | ||
| Q4 24 | $5.8M | $24.7M | ||
| Q3 24 | — | $28.3M | ||
| Q2 24 | — | $25.8M | ||
| Q1 24 | — | $22.7M |
| Q4 25 | $-832.7K | $-554.0K | ||
| Q3 25 | — | $-1.8M | ||
| Q2 25 | — | $-1.5M | ||
| Q1 25 | — | $-1.5M | ||
| Q4 24 | $-2.8M | $-756.0K | ||
| Q3 24 | — | $1.7M | ||
| Q2 24 | — | $343.0K | ||
| Q1 24 | — | $-1.7M |
| Q4 25 | 33.5% | 21.1% | ||
| Q3 25 | — | 14.3% | ||
| Q2 25 | — | 15.6% | ||
| Q1 25 | — | 16.1% | ||
| Q4 24 | 31.7% | 14.7% | ||
| Q3 24 | — | 22.0% | ||
| Q2 24 | — | 17.6% | ||
| Q1 24 | — | 13.5% |
| Q4 25 | -14.6% | -2.2% | ||
| Q3 25 | — | -9.9% | ||
| Q2 25 | — | -8.4% | ||
| Q1 25 | — | -7.2% | ||
| Q4 24 | -63.9% | -2.1% | ||
| Q3 24 | — | 6.8% | ||
| Q2 24 | — | 2.0% | ||
| Q1 24 | — | -5.8% |
| Q4 25 | -6.8% | -3.0% | ||
| Q3 25 | — | -11.0% | ||
| Q2 25 | — | -9.3% | ||
| Q1 25 | — | -8.0% | ||
| Q4 24 | -48.9% | -3.1% | ||
| Q3 24 | — | 5.9% | ||
| Q2 24 | — | 1.3% | ||
| Q1 24 | — | -7.6% |
| Q4 25 | $-0.09 | $-0.01 | ||
| Q3 25 | — | $-0.05 | ||
| Q2 25 | — | $-0.05 | ||
| Q1 25 | — | $-0.04 | ||
| Q4 24 | $-0.31 | $-0.02 | ||
| Q3 24 | — | $0.04 | ||
| Q2 24 | — | $0.01 | ||
| Q1 24 | — | $-0.06 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | ||
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $10.7M | $10.7M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $66.4M | $37.0M |
| Total Assets | $77.6M | $57.1M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $10.7M | $10.7M | ||
| Q3 25 | — | $13.6M | ||
| Q2 25 | — | $12.5M | ||
| Q1 25 | — | $11.4M | ||
| Q4 24 | $19.9M | $15.7M | ||
| Q3 24 | — | $12.3M | ||
| Q2 24 | — | $11.9M | ||
| Q1 24 | — | $6.6M |
| Q4 25 | $66.4M | $37.0M | ||
| Q3 25 | — | $37.0M | ||
| Q2 25 | — | $30.4M | ||
| Q1 25 | — | $31.5M | ||
| Q4 24 | $66.9M | $32.6M | ||
| Q3 24 | — | $29.1M | ||
| Q2 24 | — | $23.5M | ||
| Q1 24 | — | $20.6M |
| Q4 25 | $77.6M | $57.1M | ||
| Q3 25 | — | $57.5M | ||
| Q2 25 | — | $52.6M | ||
| Q1 25 | — | $54.0M | ||
| Q4 24 | $74.2M | $59.2M | ||
| Q3 24 | — | $57.1M | ||
| Q2 24 | — | $53.0M | ||
| Q1 24 | — | $50.7M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | ||
|---|---|---|
| Operating Cash FlowLast quarter | $-1.9M | $2.3M |
| Free Cash FlowOCF − Capex | — | $2.2M |
| FCF MarginFCF / Revenue | — | 12.0% |
| Capex IntensityCapex / Revenue | — | 0.5% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | $-1.2M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-1.9M | $2.3M | ||
| Q3 25 | — | $-1.3M | ||
| Q2 25 | — | $1.8M | ||
| Q1 25 | — | $-3.5M | ||
| Q4 24 | $-1.7M | $865.0K | ||
| Q3 24 | — | $4.3M | ||
| Q2 24 | — | $1.4M | ||
| Q1 24 | — | $-2.4M |
| Q4 25 | — | $2.2M | ||
| Q3 25 | — | $-1.5M | ||
| Q2 25 | — | $1.7M | ||
| Q1 25 | — | $-3.5M | ||
| Q4 24 | — | $470.0K | ||
| Q3 24 | — | $4.1M | ||
| Q2 24 | — | $1.2M | ||
| Q1 24 | — | $-2.5M |
| Q4 25 | — | 12.0% | ||
| Q3 25 | — | -9.6% | ||
| Q2 25 | — | 10.5% | ||
| Q1 25 | — | -18.8% | ||
| Q4 24 | — | 1.9% | ||
| Q3 24 | — | 14.4% | ||
| Q2 24 | — | 4.5% | ||
| Q1 24 | — | -11.1% |
| Q4 25 | — | 0.5% | ||
| Q3 25 | — | 1.4% | ||
| Q2 25 | — | 1.0% | ||
| Q1 25 | — | 0.3% | ||
| Q4 24 | — | 1.6% | ||
| Q3 24 | — | 0.7% | ||
| Q2 24 | — | 1.1% | ||
| Q1 24 | — | 0.6% |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | 2.57× | ||
| Q2 24 | — | 4.20× | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
RCON
Segment breakdown not available.
RMTI
| US | $15.9M | 87% |
| Non Us | $2.4M | 13% |